💌 June Health secures insurer backing | Huawei expands in women's health | Clair Health raises $11.6m
The global weekly briefing on women's health innovation and Femtech
Welcome to issue #152 of FutureFemHealth, (w/c June 24 2026) - the global weekly briefing on women’s health innovation.
🌟 In this week’s briefing:
🏆 Clair Health raises $11.6m – sparking debate about continuous hormone monitoring
🏥 June Health secures CAD$2.4m with insurer backing
📱 Huawei expands women’s health partnerships
💉 HPV vaccination reduces cervical cancer deaths to near zero in UK
Share your news: anna@futurefemhealth.com
This week’s newsletter is powered by The Longevity Show:
The UK’s first longevity festival takes place in London this week - on 26 & 27 June.
Women’s health will be central - with a dedicated Women’s Health Summit led by Hertility, as well as an immersive Expo, headline talks, movement and recovery experiences, and a B2B Conference for founders, investors, clinicians and innovators shaping the future of health.
🎟️ FutureFemHealth readers can get 20% off tickets with code FFH20. Book here
💰 Capital flows
📌 US: Clair Health raises $11.6m for its wearable hormone monitoring platform. Few stories have sparked as much debate as this one. Is it a continuous hormone monitor (it doesn’t monitor hormones directly), is it not, and - does it even matter? Either way, the size of this round suggests investors are placing some big bets on hormone intelligence - this is a story that will run and run. (Continue reading: Fortune)
Plus…🔒 ICYMI: What actually counts as continuous hormone monitoring? In this week’s FutureFemHealth Pro analysis, we break down the three approaches emerging across the field, why everyone is debating definitions, and whether continuous hormone monitoring should be defined by what we measure or what we learn. (Continue reading: FutureFemHealth Pro)
📌 GERMANY: Nuvisan awarded $25m from the Gates Foundation for non-hormonal contraceptive drug discovery. There’s still substantial unmet need for alternatives to hormonal contraception, but history shows that scientific innovation alone isn’t enough. Products such as Evofem’s Phexxi show how the commercial challenges around adoption and reimbursement. Nice to see then, this Gates Foundation grant which suggests there’s still a strong belief in a need for a new generation of options. (Continue reading: Nuvisan)
📌 CANADA: June Health raises CAD$2.4m with strategic investment from Securian Canada. Women’s health startups have spent years trying to convince employers that better support can improve productivity and retention. Now insurers seem to be paying attention too. The funding round may be relatively modest, but seeing an insurer invest directly in the space feels like another signal that women’s health is finally being viewed as a mainstream healthcare and benefits opportunity. (Continue reading: June Health)
📌 AUSTRALIA: Oli secures an additional $2m in government funding for maternal monitoring device manufacturing. Hot on the heels of its recent $6.5m Series A3, Oli has now secured a further $2m non-dilutive grant from the Australian Government’s Industry Growth Program to establish manufacturing capabilities in Sydney. Combined with a previous NSW Medical Devices Fund grant, the company has now attracted more than $11.5m in government support. It’s showing how public funding can help de-risk women’s health innovation, especially in areas like maternal health where the clinical and societal impact extends well beyond the healthcare system. (Continue reading: FutureFemHealth)
📌 US: Rejoni secures $25m to tackle post-surgical uterine scarring. Rejoni’s Juveena system is designed to prevent intrauterine adhesions (sometimes called Asherman’s syndrome), a condition where scar tissue forms inside the uterus following surgery and can affect fertility and reproductive health. The company is nearly ready to commercialise as the FDA has accepted the company’s premarket approval application earlier this year. New and existing investors include ClayystBio, Amed Ventures and FemHealth Ventures. (Continue reading: Rejoni)
📌 AUSTRALIA: Ovum AI raises $4m seed round for its AI-powered women’s health platform. Ovum is one of a growing number of startups attempting to build longitudinal women’s health records, creating a single place for women to track symptoms, medical history and reproductive health over time. Just a year after raising a $1.7m pre-seed round, the company has secured a further $4m at triple its previous valuation. Since launching last August, Ovum has attracted more than 20,000 users and recorded over 113,000 AI health conversations. The round was led by Admiralty Capital Group, with participation from Antler, Giant Leap and others. (Continue reading: Business News Australia)
🌟 Industry moves and strategic shifts
📌 GLOBAL: Huawei expands its wearable ecosystem with new women’s health partnerships. Huawei doesn’t immediately spring to mind when it comes to women’s health wearables - although the tech giant has offered menstrual tracking features for several years. Now, it’s intentionally expanding its strategy and looking to third-parties - adding integrations with Clue, Life: Period Tracker and The Ginger Club to its WATCH FIT 5 Series. (Continue reading: Huawei)
📌 NETHERLANDS: Sibyl pilots pregnancy loss support platform with Dutch healthcare providers. Pregnancy loss is one of the most common yet least supported experiences in women’s health. Sibyl is now partnering with a gynaecology clinic and midwifery practice to test a model that integrates personalised digital support into routine care following miscarriage and other forms of pregnancy loss. The pilot will track patient-reported outcomes and engagement, helping build evidence around whether digital interventions can improve support during the weeks and months after loss. (Continue reading: FutureFemHealth)
🩸 Research and women’s health news
📌 UK: HPV vaccination found to reduce the risk of dying from cervical cancer before age 30 to almost zero. We’ve known for years that HPV vaccination prevents cervical cancer. What’s new here is evidence that it’s now saving lives. Researchers estimate the vaccine has already prevented around 200 cervical cancer deaths in England, while no women aged 20-24 died from cervical cancer between 2020 and 2024 for the first time on record. For all the discussion around new diagnostics and therapeutics, this is a reminder that some of the biggest gains in women’s health still come from prevention. (Continue reading: The Guardian)
📌 US: Healthcare affordability falls to a five-year low, with women hit hardest. New research from West Health and Gallup found that just 42% of women are now considered able to consistently afford the healthcare and prescription medicines they need, compared with 57% of men. The gap has widened steadily since 2021 and reached its highest level on record in 2025. “Without meaningful reforms that better address healthcare delivery, high prescription drug prices and rising insurance premiums, Americans will continue to struggle and affordability will only continue to deteriorate.” (Continue reading: West Health-Gallup)
📌 GLOBAL: World Athletics studies return to sport after pregnancy. The governing body has launched a new research initiative exploring how pregnancy, childbirth and motherhood affect elite athletes’ careers. The project will combine athlete surveys with performance data to better understand everything from training and recovery to rankings, sponsorship and financial support. As more athletes compete at the highest levels before and after pregnancy, the focus is increasingly shifting from whether women can return to sport to how sporting organisations can better support them when they do. (Continue reading: World Athletics)
💡 Perspectives
📌 PERSPECTIVES: Who’s making decisions about women’s health? According to an analysis by menopause advocate Johanna Wicks, mostly men. Looking at 13 pharmaceutical companies that manufacture menopause hormone therapies, Johanna found that none had achieved gender parity at executive level and only one had a female CEO. To be clear, this isn’t about excluding men from women’s health, or even from leading in women’s health. But when an entire industry serves a predominantly female patient population, it’s fair to ask whether women are sufficiently represented in the rooms where strategic decisions get made. (Continue reading: Johanna Wicks)
📆 Save the date
📌 The Nexus Collective Kick Off - Day 1, London, Friday 26 June. A day for founders in medtech, biotech or deeptech with a focus on regulated sectors and clinical trials. Register here.
That’s all for this week! If you’ve missed any previous newsletter issues catch them all at futurefemhealth.com and do make sure to follow us on LinkedIn and you can connect with me directly.
Anna
This newsletter is for informational purposes only and should not be considered medical or financial advice.